What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Fenfluramine demonstrated a clear clinical advantage in reducing convulsive seizures compared to placebo in two Phase 3 trials, with significant reductions in seizure frequency. Additionally, it may be more effective than the comparator, cannabidiol plus clobazam, although direct comparisons are limited. The evidence supports a strong therapeutic impact, particularly in patients who have not responded to standard treatments.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for fenfluramine fall within the range considered acceptable by NICE, suggesting it provides good value for money. The committee noted that the ICER was within the range of £20,000 to £30,000 per QALY gained, which is typically acceptable for Healthcare resources.
Is there quality-of-life evidence payers weigh? — Quality of life
The evidence indicates that fenfluramine may improve quality of life for patients with Dravet syndrome and their carers, as shown by improvements in PedsQL scores in one of the trials. However, the results were not statistically significant in the second trial, indicating moderate but not overwhelming evidence of benefit.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Fenfluramine has a manageable safety profile, with adverse events reported at similar rates to placebo. While some patients discontinued treatment due to adverse events, the overall incidence was low, indicating acceptable safety and tolerability.
Was the drug compared against what payers expect? — Comparator Selection
The trials compared fenfluramine against appropriate standard care options, including placebo and the established treatment of cannabidiol plus clobazam. The committee agreed that these comparators were relevant and reflective of current clinical practice.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trials included a representative population of children and young adults with Dravet syndrome, and the evidence considered various subgroups. However, there were some limitations in subgroup analyses, which slightly affect the generalizability.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Fenfluramine can be integrated into existing treatment pathways as an add-on therapy without requiring significant changes to current practices. The committee noted that it fits well within the standard care framework for Dravet syndrome.
Are the wider system costs understood? — Resource Use and Cost Implications
The budget impact of fenfluramine is manageable, and the committee noted that it is likely to provide net savings in the long term due to its effectiveness in reducing seizure frequency and associated healthcare costs.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is strong, supported by multiple Phase 3 trials with low bias risk. The committee found the overall quality of evidence to be robust, although some uncertainties remain regarding long-term effects.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there are some uncertainties regarding the long-term effects and the relationship between seizure frequency and mortality, the overall context supports the use of fenfluramine, particularly given the high unmet need in this patient population.
